Hospital
Cumberland Medical Center, INC.
Cumberland Medical Center, INC. was paid $6.06M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoCUMBERLAND MEDICAL CENTER, INC.
CROSSVILLE, TN 38555
CROSSVILLE, TN 38555
33aNPI1871596403assigned 05/27/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.06M
24GClaims179,198
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#38 of 71
Median peer was paid$6.96M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,906 | $1.07M | |
| 2019 | 37,083 | $1.08M | |
| 2020 | 23,464 | $693K | |
| 2021 | 13,313 | $427K | |
| 2022 | 22,223 | $758K | |
| 2023 | 27,590 | $1.09M | |
| 2024incomplete | 17,619 | $947K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 19,592 | 18,366 | $2.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 7,518 | 6,956 | $1.29M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 11,426 | 10,782 | $822K |
| 41899 | Unlisted procedure, dentoalveolar structures | 6.0% | 761 | 720 | $366K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 1,056 | 932 | $266K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 7,199 | 6,671 | $171K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 1,728 | 1,623 | $100K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 23,218 | 21,113 | $88K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 3,430 | 3,232 | $72K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,505 | 4,193 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,522 | 2,359 | $39K |
| 80053 | Comprehensive metabolic panel | <1% | 13,928 | 12,698 | $37K |
75 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 4,409 | $34K |
| 84484 | <1% | 3,029 | $33K | |
| 87276 | <1% | 4,092 | $26K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,291 | $22K |
| 80306 | <1% | 1,450 | $22K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,437 | $17K |
| 87275 | <1% | 4,095 | $17K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 675 | $16K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,659 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,694 | $15K |
| 81001 | <1% | 14,763 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,441 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,301 | $11K |
| 83690 | <1% | 3,484 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,838 | $11K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 270 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 808 | $7K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 100 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,136 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 94 | $4K |
| G0378 | Hospital observation service, per hour | <1% | 18 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 55 | $4K |
| 83605 | <1% | 765 | $4K | |
| 87081 | <1% | 565 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 223 | $3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $3K |
| 87040 | <1% | 226 | $2K | |
| 95816 | <1% | 15 | $2K | |
| 85610 | <1% | 1,365 | $2K | |
| 97602 | <1% | 179 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17 | $1K |
| 81025 | <1% | 399 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 94 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 543 | $1K |
| 74018 | <1% | 26 | $1K | |
| 87807 | <1% | 120 | $801.49 | |
| 82077 | <1% | 215 | $731.22 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $603.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 545 | $513.99 |
| 85730 | <1% | 153 | $417.63 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 178 | $402.93 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 280 | $402.00 |
| 87186 | <1% | 42 | $372.59 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 57 | $364.38 |
| 82784 | <1% | 16 | $356.74 | |
| 83735 | <1% | 144 | $294.36 | |
| 81003 | <1% | 502 | $269.54 | |
| 85027 | <1% | 60 | $205.56 | |
| 84703 | <1% | 85 | $201.11 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 88 | $181.74 |
| 82550 | <1% | 79 | $175.40 | |
| 82785 | <1% | 14 | $154.64 | |
| 87077 | <1% | 45 | $152.90 | |
| 72100 | <1% | 15 | $123.12 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 121 | $111.73 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 95 | $103.12 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 106 | $96.87 |
| 86364 | <1% | 14 | $96.34 | |
| 86140 | <1% | 41 | $85.49 | |
| J1980 | Injection, hyoscyamine sulfate, up to 0.25 mg | <1% | 14 | $64.52 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 50 | $63.20 |
| 86003 | <1% | 14 | $53.06 | |
| 84439 | <1% | 15 | $41.52 | |
| 82150 | <1% | 14 | $36.86 | |
| 85652 | <1% | 16 | $31.17 | |
| 86200 | <1% | 14 | $15.18 | |
| 86431 | <1% | 26 | $13.20 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 70 | $8.17 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,045 | $1.10 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 44 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 31 | $0.00 |
| A9270 | Non-covered item or service | 0% | 6,054 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 226 | $0.00 |
| 29581 | 0% | 45 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRINGER, RICK (VP REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Parkwest Medical Center | Knoxville, TN | $29.88M |
| Fort Sanders Regional Medical Center | Knoxville, TN | $26.76M |
| Leconte Medical Center | Sevierville, TN | $19.05M |
| Morristown Hamblen Hospital Association | Morristown, TN | $17.83M |
| Methodist Medical Center | Oak Ridge, TN | $11.32M |
| Roane County Medical Center | Harriman, TN | $9.24M |
| Fort Loudoun Medical Center | Lenoir City, TN | $5.86M |
| Claiborne Medical Center | Tazewell, TN | $3.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.